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One of the most common extraintestinal manifestations of inflammatory bowel disease is
iron deficiency anemia. It is often an untreated condition that significantly impairs patients’
quality of life and elevates mortality and morbidity. Although it is often accompanied by
mild symptoms (e.g., fatigue, lethargy), it can provoke severe health conditions, such
as dyspnea, palpitation, angina, and mental disorders, and increases hospitalization
and mortality rate as well. As anemia develops through several pathomechanisms,
such as occult bleeding, chronic inflammation, and medicines (e.g., methotrexate),
treating anemia effectively requires to manage the underlying pathological changes
as well. Based on international publications and data, it is a frequent condition and
more frequent in pediatrics. According to Goodhand et al., iron deficiency is present
in more than 60% of children, whereas only 14% of them received oral iron therapy.
Compared to adult patients, 22% have iron deficiency, and 48% of them received oral
and 41% intravenous iron therapy. Miller et al. also highlighted that among young patients
iron deficiency anemia is a frequent condition, as almost 50% of the patients were
anemic in their cohort. European Crohn’s and Colitis Organisation’s statements are clear
regarding the diagnosis of iron deficiency anemia, and the iron supplementation as well.
Third-generation parenteral iron supplementations seem to be safer and more effective
than oral iron pills. Oral iron in many cases cannot replace the iron homeostasis as well;
furthermore, it can provoke dysbiosis, which can potentially lead to relapse. As a result,
we claim that both oral and parenteral should be used more frequently; furthermore,
intravenous iron could replace oral medicines as well in certain cases. Despite the fact
that iron deficiency anemia is examined bymany aspects, further questions can be raised.
Can it imply underlying pathological lesions? Are both oral and intravenous iron therapy
safe and effective? When and how are they used? We demand that more studies should
be conducted regarding these issues.
Keywords: inflammatory bowel disease, iron deficiency anemia, iron supplementation, anemia, parenteral iron
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INTRODUCTION
Inflammatory bowel disease [IBD: Crohn disease (CD), ulcerative colitis (UC)] is a chronic,
immune-mediated disease that impairs patients’ quality of life (QoL), and it is associated with many
comorbidities. One of the most common concomitant diseases is iron deficiency anemia (IDA),
which also worsens the condition of patients and mostly remains untreated (1). It can occur at any
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stage of IBD and can be the first symptom of the disease as
well. It is often associated with frequent chronic activity, but can
also be encountered without clinical signs of activity. In such
cases, the IDA diagnosis raises the possibility of asymptomatic,
subclinically occurring inflammation and mucosal damage in
the presence of long-term chronic activity that damages the
condition and function of the intestine (1).
Frequency of IDA
At the time of the diagnosis, the prevalence of IDA in patients
younger than 18 years is approximately 41–75% (2), whereas in
adult patients it is also high; however, it varies with wide ranges,
from 6 to 74% (3). According to a Swedish study, conducted
by Sjöberg et al., the prevalence of IDA is almost twice as high
in children (55%) as in adult patients (27%) at the time of the
diagnosis. Furthermore, they found significant difference as well
in the prevalence of IDA among patients with CD, compared to
UC, following the first year after the diagnosis. They also found
that anemia in CD was more common in colonic engagement,
and in UC, extensive inflammation increased the prevalence
(4). Eriksson et al. conducted a study to assess the incidence,
prevalence, and clinical outcome of anemia in IBD, comparing
CD and UC, and they found as well that CD is associated with
higher prevalence and a worse outcome regarding the resolution
of anemia (5).
Symptoms and Clinical Role
Generally speaking, it should be highlighted that patients with
IDA claim to have decreased QoL. In a Spanish study, conducted
by García-López et al., it was found that treating IDA improves
the QoL, regardless of the symptoms of IBD (6).
As iron plays key role in the function of many cells (e.g.,
erythrocyte, macrophage), cellular proteins, and enzymes (e.g.,
cytochromes, myoglobin), the symptoms of IDA vary over a
wide range (7, 8). Key symptoms, such as shortness of breath,
palpitation, tachycardia, and even angina, occur because of the
hypoxemia. As a result of the decreased blood oxygen level, there
is a compensatory decrease in intestinal blood flow, which may
cause motility disorder, malabsorption, nausea, weight loss, and
abdominal pain. Central hypoxia may lead to headache, vertigo,
and lethargy, as well as cognitive impairment, and several studies
proved that normalizing anemia improves cognitive functions
(9–12) (Table 1).
Michailidou et al. compared the risk of postoperative
complications between anemic and nonanemic patients. In
their study consisting of more than 15,000 people, it was
found that patients with anemia were more likely to have
postoperative complications (e.g., morbidity and mortality rate;
undesirable cardiovascular, renal, pulmonary, and wound healing
complications; postoperative sepsis and shock) (13).
Etiology of Anemia in IBD
The most common causes of anemia in IBD are IDA, chronic
inflammation, and anemia of mixed origins, whereas B12
deficiency and folic acid deficiency (mostly due to medications)
belong to the less common causes. In addition, it may also occur
TABLE 1 | Symptoms of iron deficiency anemia.
Nervous system Headache, lethargy, vertigo, syncope, cognitive
impairment, depression
Cardiovascular system Palpitation, tachycardia, hypotension, angina, ischemic
electrocardiographic signs, cardiac failure
Respiratory system Shortness of breath
Skin Paleness, alopecia, cold intolerance
Gastrointestinal
symptoms
Anorexia, nausea, motility disturbances, angular
stomatitis, glossitis (Plummer–Vinson syndrome)
Immune system Disorder of the innate and adaptive immune system
Urogenital symptoms Decreased libido, menstrual disorders
General symptoms Decreased quality of life, lower physical activity
TABLE 2 | Ethiology of anemia in IBD.
Most common causea of anemia in IBD - Iron deficiency anemia
- Anemia of chronic inflammation
- Anemia of mixed origins
Less common causes - Folic acid/B12 deficiency





because of hemolysis, myelodysplastic syndrome/medication-
induced aplasia, protein starvation, and liver disease (e.g.,
primary sclerosing cholangitis) (14, 15) (Table 2).
Pathophysiology of IDA
In IBD, the IDA can develop through several
pathomechanisms (16):
I. Intestinal mucosal damage resulting in occult, chronic
blood loss
II. Chronic inflammation
a) Reduced iron-absorbing capacity of enterocytes
b) Iron is trapped in macrophages
c) Inhibition of the erythropoietin and the
differentiation/proliferation of the erythroid progenitor cells
Cytokines and acute-phase proteins cause changes in iron
homeostasis during inflammation. Hepcidin plays the central
role in the regulatory process. It is an antimicrobial protein,
produced by the liver in case of iron surplus and in inflammation,
triggered by interleukin 6 and lipopolysaccharides. Hepcidin
binds to the iron-transporting ferroportin receptor and degrades
it, which results in decreased iron transport from the enterocytes
to the circulation, and causes retention of the iron in the
monocytes/macrophages; these processes are enhanced by anti–
tumor necrosis factor α. In addition, hepcidin reduces the
absorption of the Fe2+ from the duodenum, through the
inhibition of the DMT1 (divalent metal transporter 1) (17).
Transferrin is the main iron carrier protein, and during
inflammation, acute-phase proteins (e.g., α-1 antitrypsin) bind
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TABLE 3 | Pathomechanisms of different type of anemias in IBD.
Iron deficiency anemia Chronic blood loss





Iron retention in monocytes/macrophages
Reduced absorption of Fe2+ (inflammation)
Reduced biological half-life of erythrocytes (e.g.,
erythrophagocytosis)
Inhibition of erythropoiesis
Other origin Vitamin deficiency (B12, folic acid)
Drug-induced bone marrow suppression
(methotrexate, azathioprine)
to transferrin receptors and inhibit the iron uptake in the
erythroid progenitors cells, resulting in reduced differentiation
and proliferation (18).
Diagnosis/Differential Diagnosis in Anemia
Anemia and iron homeostasis should be monitored regularly in
IBD (depending on activity and the type of the treatment):
- At the time of diagnosis
- During activity—every 3 months
- In remission—every 6 to 12 months
Vitamin B12 and folic acid should be monitored every year, in
case of presence of risk factors (e.g., resection, pouch, extensive
ileal disease) every 3–6 months.
The diagnosis of anemia is assessed by the World Health
Organization (WHO) diagnostic criteria, depending on the
gender and age of the patients (Table 3).
Differential Diagnosis in Anemia
According to the European Crohn’s and Colitis Organization
(ECCO) recommendations, the following parameters should be
monitored if hemoglobin is below normal (Table 4): erythrocyte
count, serum ferritin, C-reactive protein (CRP) concentration,
transferrin saturation, reticulocyte count, erythrocyte width
distribution, and mean corpuscular volume. Ferritin is an acute-
phase protein produced by the liver, and it is responsible
for binding and storing iron in the liver, spleen, and
reticuloendothelial system. It is reduced in case of iron deficiency
and elevated in inflammation. Hence, in determining the cause
of anemia in IBD, it is important to assess disease activity based
on disease scoring systems (Crohn’s Disease Activity Index and
Mayo score) and serum CRP and fecal calprotectin levels. In
case of inflammation, transferrin saturation helps in differential
diagnosis. Transferrin saturation (accepted normal range =
20–45%) is lower in inflammation, liver disease, malignancy,
nephrotic syndrome, and anorexia, whereas it is elevated in iron
deficiency and pregnancy (19).
IDA (19):
a) Anemia based on WHO criteria (low hemoglobin and
hematocrit). Clinically and endoscopically, no inflammation
TABLE 4 | World Health Organization’s anemia criteria.
Hemoglobin (g/dL) Hematocrit(%)
Children between 6 months and 5 years 11 33
Children between 5 and 11 years 11.5 34
Children between 12 and 13 years 12 36
Pregnant women 11 36
Women 12 33
Men 13 39
FIGURE 1 | Differential diagnosis of IDA and chronic inflammation–associated
iron deficiency.
can be found, CRP level is normal, and serum ferritin is
<30 µg/L.
b) Anemia based on WHO criteria. Clinically and/or
endoscopically, inflammation can be found, CRP is elevated,
and ferritin is <100 µg/L.
Anemia associated with chronic inflammation:
- Anemia based on WHO criteria. Clinically and/or
endoscopically, inflammation can be found, CRP is elevated,
ferritin is >100 µg/L, and transferrin saturation is <20%.
Anemia of mixed origin:
- Anemia based on WHO criteria. Clinically and/or
endoscopically, inflammation can be found, CRP is elevated,
and ferritin is between 30 and 100 µg/L (Figure 1).
Iron Supplementation
Goodhand et al. pointed out how undertreated the IDA is in IBD.
In children (88%) and adolescents (83%), the incidence of IDA is
much higher compared to that in adults (55%), and only a small
proportion of patients received oral (children 13%, adolescents
30%, adults 48%) or parenteral iron supplementation (children
0%, adolescents 30%, adults 41%) (20).
In addition to improving the QoL, the goal of iron
supplementation is to normalize hemoglobin, serum ferritin, and
transferrin saturation and to refill iron stores (ferritin >100 g/L).
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TABLE 5 | Administration of parenteral iron replacement.
Hemoglobin (g/dL) Body weight <70 kg Body weight ≥70 kg
10–12 (Female) 1,000mg 1,500 mg
10–13 (Male)
7–10 1,500mg 2,000 mg
Based on the recommendation of the ECCO (19):
Iron supplementation is recommended to all patients with
anemia associated with iron disorder. If iron deficiency exists
without anemia, iron supplementation requires consideration of
the patient’s individual clinical status, as there is no evidence in
IBD regarding the efficacy of the treatment (19).
Oral iron supplementation is recommended to every patient
with IDA with hemoglobin >10 g/dL in case of remission
(no clinical/endoscopic activity, normal CRP level). The
recommended oral iron intake is 100 mg/day for adults (higher
doses are not recommended), and 2–3 mg/kg body weight per
day in children. An acceptable therapeutic response is an increase
of 2 g/dL in hemoglobin over 4 weeks. If there is intolerance,
adverse effects or unsatisfactory therapeutic response is present,
intravenous iron therapy is recommended (19).
Parenteral iron supplementation is recommended as a first
choice in IDA in case of active IBD (elevated CRP levels and/or
clinically active IBD), or hemoglobin level <10 g/dL, or previous
intolerance to iron supplementation is present. If the elevation
is <2 g/dL in hemoglobin level after 4 weeks’ therapy, it is
recommended to complete the treatment with Erythropoietin
(EPO) stimulant. The required iron intake is estimated based
on the body weight and the hemoglobin, as it is more effective
in patients with IBD suffering from iron deficiency than the
traditional Ganzoni formula (19) (Table 5).
Following the resolution of IDA with parenteral iron
supplementation, ferritin level is recommended to be maintained
above 400 µg/L to prevent short-term recurrence. After
successful iron supplementation, patients should be monitored
every 3 months in the first year following the correction and
every 6–12 months thereafter (including hemoglobin, ferritin,
transferrin saturation, CRP). Recurrent anemia may indicate
underlying inflammation despite clinical and biochemical
remission. The goal of preventive treatment is to keep ferritin
and hemoglobin at normal levels. Reinitiation of intravenous iron
supplementation is recommended in cases where the ferritin level
falls below 100 µg/L or the hemoglobin level is <12–13 g/dL
(female/male) (19).
When considering between oral and intravenous iron therapy,
the advantages and disadvantages of the therapeutic approaches




Easier to implement in daily practice
More accessible
Effective in good intestinal absorption
b. Disadvantages
Compliance issues
Certain foods reduce iron absorption (e.g., tea, coffee,
dairy products, fiber)
Certain medications reduce iron absorption
i. Multivitamin/dietary supplements (Ca2+, Zn2+, Cu2+)













Fast correction of iron homeostasis
Safe and well tolerated
Fewer side effects
Effective in inflammation
The condition of themucosa does not influence the efficacy
b. Disadvantages
Higher cost
Harder to implement in daily practice
Potential risk of iron overload
Potential risk of anaphylaxis
Possibility of hypophosphatemia
Parenteral Iron Supplementation
Intravenous iron supplementations consist of an Fe3+ core
and a carbohydrate layer. The side effect profile, clearance,
tolerable dose, and duration of the infusion are dependent on
the magnitude of the core and quality of the carbohydrate layer.
The different generations of intravenous iron supplementation
comprised different carbohydrate layers (24).
- First generation—high-molecular-weight iron dextran







The disadvantage of the HMWID is the higher probability of
anaphylactic reaction/side effects; because of that, it is advised
to use higher-generation products. The representatives of the
second generation are more efficient with fewer side effects;
however, they are not as stable complexes as the representatives
of the third-generation preparations; consequently, they can only
Frontiers in Medicine | www.frontiersin.org 4 July 2021 | Volume 8 | Article 686778
Resál et al. Iron Deficiency Anemia in IBD
be administered in low doses, and so they require frequents
visits. Third-generation preparations are much more efficient,
with minimal side effect profile; furthermore, they can be
implemented easier in the daily practice. These formulations
are more stable, so they can be administered in higher doses,
resulting in faster correction of the iron homeostasis, and the
duration of the infusion is lesser (23, 25).
DISCUSSION
Anemia and IDA are common consequences of IBD in the
developed world. Despite that we know how frequent it is,
physicians tend to pay less attention to treat it, even though
it affects the course of the disease and heavily reduces the
patients’ QoL. Although modern medicine knows many facts
about the pathophysiology of anemia and IDA, and there are
many efficient agents in the therapeutic arsenal, it still raises
relevant questions. However, the ECCO’s recommendations are
clear; we would like to highlight that it should be still a matter
of individual judgment, and in certain cases, parenteral iron
supplementation should be the choice, instead of oral, because
of the side effects. Based on international publications and
data, as intravenous iron supplementation tends to be more
efficient and safe in IBD, we claim that more studies should
be conducted regarding third-generation agents and clarify the
boundary line in the recommendations. However, to sum up, we
demand that both oral and intravenous iron treatments should be
more widespread.
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